Analyst firms · Leerink Partners · SPRB

Leerink Partners SPRB price target and rating history

Spruce Biosciences Inc. (SPRB) · Health Care

Leerink Partners rates Spruce Biosciences Inc. (SPRB) Outperform with a $160 price target, as of its latest action on Dec 3, 2025. It has published 4 rating actions on SPRB since November 2021, including 1 upgrade and 3 downgrades. Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Leerink Partners's $160 is 4% above that.

Current rating
Outperform
Price target
$160
Median target, all firms
$154.50
Actions on SPRB
4

Leerink Partners price target on SPRB

$160$81$220222023202420252026
Leerink Partners price target on SPRB, each point a stated target, November 2021 to December 2025.

Every Leerink Partners rating on SPRB

How other firms rate SPRB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Lake StreetBuy$149Sep 17, 2026
B. Riley SecuritiesBuy$160Jul 13, 2026
GuggenheimBuy$123Jun 16, 2026
Craig-HallumBuy$140Apr 27, 2026
OppenheimerOutperform$283Dec 23, 2025
Leerink PartnersOutperform$160Dec 3, 2025

Questions about Leerink Partners and SPRB

What is Leerink Partners's price target for SPRB?
Leerink Partners's latest stated price target for Spruce Biosciences Inc. (SPRB) is $160, from its action on Dec 3, 2025.
What is Leerink Partners's rating on SPRB?
Leerink Partners rates SPRB Outperform, a bullish rating, as of Dec 3, 2025.
When did Leerink Partners last change its view on SPRB?
On Dec 3, 2025, Leerink Partners upgrades to Outperform from Market Perform, price target $160.
How does Leerink Partners's SPRB target compare with other analysts?
Across 6 firms with a SPRB price target in the last 12 months, the median target is $154.50. Leerink Partners's $160 is 4% above that.

More SPRB rating histories

All Leerink Partners ratingsSPRB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.